Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aromatase inhibitors.

G H Cunnick1, K Mokbel

  • 1St George's Breast Cancer Centre, St George's Hospital, London, UK.

Current Medical Research and Opinion
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

New aromatase inhibitors are effective second-line treatments for postmenopausal breast cancer, offering better tolerability than megestrol acetate (MA). These advanced therapies show improved efficacy and survival benefits, establishing them as key hormonal agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter re: A critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

ESMO open·2025
Same author

Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines.

Clinical radiology·2021
Same author

An evaluation of patient reported outcomes by utilizing breast Q following oncoplastic breast conserving surgery and arc-LICAP flap partial breast reconstruction.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2020
Same author

Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2013
Same author

Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.

Oncology reports·2013
Same author

Comment on prognostic and therapeutic implications of mTORC2 and rictor expression in human breast cancer.

Breast cancer research and treatment·2012
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
Same journal

Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

Current medical research and opinion·2026
See all related articles

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Breast cancer treatment in postmenopausal women often involves hormonal therapy.
  • Megestrol acetate (MA) has been a standard second-line agent.
  • Emerging evidence highlights the role of newer aromatase inhibitors (AIs).

Purpose of the Study:

  • To evaluate the efficacy and tolerability of new non-steroidal and steroidal aromatase inhibitors compared to megestrol acetate (MA) in postmenopausal breast cancer.
  • To assess the role of third-generation AIs in first-line and neoadjuvant settings.
  • To explore potential applications in breast cancer prevention.

Main Methods:

  • Comparative analysis of clinical trial data for aromatase inhibitors (letrozole, exemestane, anastrozole) versus megestrol acetate (MA).
  • Review of studies on first-line and neoadjuvant therapy outcomes.

Related Experiment Videos

  • Ongoing head-to-head trials and adjuvant tamoxifen comparisons.

    • Main Results:

    • New non-steroidal and steroidal AIs demonstrate comparable or superior efficacy to MA as second-line agents.
    • These AIs offer improved tolerability and fewer adverse effects than MA.
    • Exemestane and anastrozole show a survival advantage over MA.
    • Growing evidence supports third-generation AIs in first-line and neoadjuvant settings for hormone receptor-positive breast cancer.

    Conclusions:

    • Third-generation aromatase inhibitors are established and preferred second-line hormonal agents for postmenopausal breast cancer due to superior efficacy and tolerability.
    • These agents show promise in first-line and neoadjuvant therapies.
    • Further research, including prevention trials, is warranted.